

## Incipient and subclinical tuberculosis: a narrative review

Malay Sarkar

Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India

### Abstract

*Mycobacterium tuberculosis* has been known to infect humans for eons. It is an airborne infectious disease transmitted through droplet nuclei of 1 to 5  $\mu\text{m}$  in diameter. Historically, tuberculosis (TB) was considered a distinct condition characterized by TB infection and active TB disease. However, recently, the concept of a dynamic spectrum of infection has emerged, wherein the pathogen is initially eradicated by the innate or adaptive immune system, either in conjunction with or independently of T cell priming. Other categories within this spectrum include TB infection, incipient TB, subclinical TB, and active TB disease. Various host- and pathogen-related factors influence these categories. Furthermore, subclinical TB can facilitate the spread of infection within the community. Due to its asymptomatic nature, there is a risk of delayed diagnosis, and some patients may remain undiagnosed. Individuals with subclinical TB may stay in this stage for an indeterminate period without progressing to active TB disease, and some may even experience regression. Early diagnosis and treatment of TB are essential to meet the 2035 targets outlined in the end-TB strategy. This strategy should also include incipient and subclinical TB. This review will focus on the definition, natural history, burden, trajectory, transmissibility, detection, and management of early-stage TB.

**Key words:** *Mycobacterium tuberculosis*, transmission, incipient TB, subclinical tuberculosis, early-stage TB.

Correspondence to: Malay Sarkar, Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.  
E-mail: drsarkarmalay23@rediffmail.com

### Introduction

Traditionally, tuberculosis (TB) has been classified as a binary paradigm consisting of TB infection and active TB disease. However, recent advances in our understanding of the natural history of TB have led to a more nuanced perspective. TB is now thought of as a continuous spectrum with multiple stages [1,2]. This spectrum includes individuals who have successfully eliminated TB infection, those with TB infection, incipient TB, subclinical TB, and active TB disease [3,4]. Nonetheless, there are disparities in nomenclature, diagnostic standards, and definitions for various states of TB [5]. Latent TB infection is defined as an asymptomatic state of infection with *Mycobacterium tuberculosis*. The infection is demonstrated by a positive response to *in vivo* or *in vitro* stimulation with *M. tuberculosis* antigens, such as tuberculin skin test (TST) or interferon  $\gamma$  release assay (IGRA) [6]. Since the TST or IGRA tests cannot distinguish between individuals who have cleared *M. tuberculosis* with activation of T-helper memory cells and those who harbor latent TB bacilli, the more accurate terminology should be TB infection and not latent TB infection. Incipient TB is defined as an asymptomatic, early preclinical disease state during which pathology evolves, including mycobacterial replication or an inflammatory response [6]. There are no clinical signs or symptoms present, and radiographic or microbiological evidence of active TB disease is lacking [3]. Frascella *et al.* described incipient disease as a transition between minimal disease and subclinical disease, indicating

that incipient TB is not considered a distinct disease state [7]. Individuals with incipient TB are likely to progress to subclinical TB or active TB disease in the absence of further intervention [3]. An individual with incipient TB infection has viable TB bacilli characterized by slow metabolic activity and replication, with the bacilli alternating between periods of dormancy and metabolic activity [8]. These patients are likely not infectious, and there are currently no validated diagnostic tools available for diagnosing incipient TB patients. The exact incidence of incipient TB is unknown; however, active TB progresses through an incipient state. Additionally, individuals with incipient TB may experience spontaneous resolution, suggesting that the incidence of incipient TB is likely to be higher than that of active TB disease. The TST and IGRA tests are positive in patients with incipient TB. Drain *et al.* defined subclinical pulmonary TB as a state of disease due to viable *M. tuberculosis* that does not cause TB-related symptoms but does result in other abnormalities detectable through existing radiologic or microbiologic assays [3]. Patients with subclinical TB disease are asymptomatic upon symptom screening [3]. Therefore, they may remain undiagnosed in a symptom-based TB screening program and continue to transmit the infection, as the bacilli are replicating and metabolically active [4]. The International Consensus for Early TB group, through a Delphi exercise involving 71 participants, classified both active TB and subclinical TB into two stages: infectious and non-infectious [5]. This classification was based on three parameters: the presence of macroscopic TB pathology, the infectiousness of the host, and the symptoms or signs of TB. Individuals with non-infec-



tious subclinical TB exhibit macroscopic pathology. Consequently, imaging is the only technique that can identify this stage. Individuals with an infectious form of subclinical TB also exhibit macroscopic pathology. Either these states may be asymptomatic or have symptoms or signs that go unrecognized or unacknowledged [5]. Moreover, the symptoms may not be sufficient to drive them to seek medical care. The TST and IGRA tests are also positive in patients with subclinical TB. Early detection of subclinical TB and the timely initiation of effective chemotherapy can interrupt the transmission of infection, prevent future infectiousness, mitigate extensive lung damage, and reduce the subsequent risk of post-TB sequelae [5,9].

Although subclinical TB is often described as an asymptomatic state, individuals with this condition are not always truly asymptomatic. In prevalence surveys, subclinical TB has frequently been defined as any case of TB without the typical symptom of a cough persisting for 2 weeks or more. For instance, in a prevalence survey conducted in Zambia, 40.5% of 257 confirmed TB patients reported no history of cough [10]. However, TB patients without a history of a cough lasting 2 weeks or more also reported other symptoms such as chest pain (46.2%), fever (24%), night sweats (27.9%), and weight loss (38.5%). Approximately 12% of individuals had no cough, fever, night sweats, or weight loss. Therefore, evaluating other TB-related symptoms is also crucial. Patients with subclinical pulmonary TB who are bacteriologically positive can transmit infection intermittently or persistently through symptoms they are unaware of, do not acknowledge, or attribute to alternative conditions [11]. Kendall *et al.* described these symptoms as too subtle to warrant medical attention or too nonspecific to prompt a clinical TB workup [12]. The subtle symptoms are usually more frequent than the classic symptoms of TB. Healthcare professionals can elicit these milder symptoms through targeted questioning; the process has not been entirely standardized. For example, patients may develop unrelated coughs due to factors such as air pollution, weather, alternative respiratory diseases, viral infection, and smoking. Moreover, patients may not recognize when their cough frequency exceeds normal. Sometimes, patients experience fleeting symptoms, which they do not consider unusual. These symptoms can be detected using a wearable cough monitor or a cough diary. Chronic or acute cough unrelated to TB pathology may also contribute to the transmission of subclinical TB. In patients with subclinical TB, chronic cough may be attributed to non-TB conditions such as chronic bronchitis and bronchiectasis, which can obscure the symp-

toms of TB. Individuals may transmit the infection due to their habitual coughing. Furthermore, the likelihood of transmission increases because these patients continue to participate in regular social activities [13,14]. Chronic cough is not uncommon in the community. In a systematic review and meta-analysis, Song *et al.* reported an overall global prevalence of chronic cough of 9.6% [95% confidence interval (CI) 7.6-11.7%] [15]. Sometimes, a viral acute respiratory infection may induce coughing and facilitate the transmission of underlying subclinical TB [14]. Smoking, which can lead to chronic cough, may also mask the TB symptoms [13]. Lin *et al.* assessed the prevalence and duration of cough following H1N1 influenza infection, enrolling 141 influenza cases, and found cough in 97.2% of cases [16]. The incidence of coughs between 1-3 weeks and  $\geq 3$  weeks was 7.8% and 8.5%, respectively. Patterson *et al.* suggested that coughing is not the sole mechanism for TB transmission [17]; TB can also be transmitted through tidal breathing, sneezing, talking, singing, yawning, and during lung function testing. An important mechanism for aerosol production is the bronchiole fluid film burst mechanism. During expiration, the small airways are filled with fluid. Early in inspiration, the bursting of the bronchiole fluid film occurs, creating an aerosol. Table 1 shows the definition of various spectrums of TB. Figure 1 shows the characteristic features of various stages of TB.

## Epidemiology and risk factors

The high burden of undiagnosed TB has significant potential to fuel the global TB burden. The large pool of subclinical TB is one example of undiagnosed TB. Frascella *et al.* reported that subclinical TB accounts for 36.1% to 79.7% (median, 50.4%) of the bacteriologically confirmed cases of prevalent TB [7]. The prevalence in African and Asian countries was 49.4% [interquartile range (IQR), 38.8-52.4%] and 56.4% (IQR, 42.8-68.5%), respectively. They could not find any association with HIV prevalence. Chest radiography identified the majority of bacteriologically confirmed TB cases, including subclinical TB (median, 89%; range, 73-98%). As a result, the current TB screening approach should include chest radiography. Stuck *et al.*, in a meta-analysis, estimated the prevalence of subclinical TB based on three case definitions [18]: i) sputum-culture-positive TB but without a self-reported cough lasting 2 weeks or more, irrespective of other symptoms; ii) sputum culture positive TB but

**Table 1.** Definition of various spectrums of tuberculosis.


	Definition
Latent TB infection	Asymptomatic state of infection with <i>Mycobacterium tuberculosis</i> demonstrated by a response to in vivo or in vitro stimulation by <i>M. tuberculosis</i> antigens as identified by a positive TST or IGRA [6].
Incipient TB	Incipient TB infection is an infection with viable <i>M. tuberculosis</i> bacteria that has not yet produced clinical symptoms, radiographic abnormalities, or microbiologic evidence consistent with active TB disease but is likely to progress to active disease in the absence of further intervention [3]. Incipient TB as an “asymptomatic, early preclinical disease state during which pathology evolves, such as mycobacterial replication or the inflammatory response. During this state, clinical signs of the disease, including TB-compatible symptoms, are still absent. Radiological abnormalities or positive microbiological tests may or may not be present. This state may either evolve and lead to symptomatic clinical TB or regress and remain asymptomatic” [6].
Subclinical TB	A state of disease due to viable <i>Mycobacterium tuberculosis</i> that does not cause TB-related symptoms but does cause other abnormalities that can be detected using existing radiologic or microbiologic assays [3].
Clinical TB	Active symptomatic disease state as a result of the mycobacterial inflammation, with the presence of TB-compatible signs and symptoms, which can be demonstrated by radiological, pathological, and/or microbiological evidence [6].

TB, tuberculosis; TST, tuberculin test; IGRA, interferon  $\gamma$  release assay.



without any self-reported cough of any duration; or iii) sputum culture positive TB in the absence of cough, fever, night sweats, weight loss, or chest pain, regardless of the duration of symptoms. The estimated unadjusted proportion of subclinical TB was 59.1% (95% CI 55.8-62.3) for individuals with no persistent cough and 39.8% (95% CI 36.6-43.0) for those with no cough of any duration. The adjusted proportions were 82.8% (95% CI 78.6-86.6) for individuals with no persistent cough and 62.5% (95% CI 56.6-68.7) for those with no cough at all. Among participants with TB, 29.1% (95% CI 25.2-33.3) of those without a persistent cough and 23.1% (95% CI 18.8-27.4) of those without any cough had positive smear examinations. Consequently, a sizable proportion of cases of TB will remain undiagnosed if the diagnosis is solely based on symptoms. Hamada *et al.* conducted a meta-analysis of 16 national and sub-national TB prevalence surveys that included data from Asian and African countries [19]. The prevalence of subclinical TB ranged from 15.1% to 56.7%, with a median of 38.1%. On multivariate analysis, current smoking was associated with both subclinical [odds ratio (OR) 1.67, 95% CI 1.27-2.40] and symptomatic TB (OR 1.49, 95% CI 1.34-1.66). However, self-reported diabetes was not found to be associated with subclinical TB (OR 0.92, 95% CI 0.55-1.55). Therefore, regardless of age or gender, current smokers are more likely to have subclinical TB and should be given priority for intensive TB screening, including chest X-rays. The results of national TB prevalence surveys in 12 Asian countries (1990 to 2012) indicated that 40% to 79% of bacteriologically positive TB cases reported the absence of TB symptoms during screening [20]. Additionally, five regional TB surveys from Tamil Nadu reported a crude median prevalence of subclinical TB of 43.1% (IQR 36-55%) [7]. The Indian National TB Prevalence Survey (2019-2021) was a population-based cross-sectional study that revealed poor healthcare-seeking behavior among many symptomatic patients, with 63.6% not seeking care. Furthermore, without chest X-rays, 42.6% of the TB cases identified in the survey would have gone unnoticed [21]. Oni *et al.* evaluated the prevalence of sub-

clinical TB disease and its outcomes among 274 asymptomatic, treatment-naïve individuals infected with HIV-1 in Cape Town, South Africa [22]. The prevalence of subclinical TB disease was found to be 8.5% (95% CI 5.1-13.0%). The majority of patients with subclinical TB were diagnosed based on positive cultures. Approximately 70% of subclinical TB patients were smear negative, compared to 16% of patients with symptomatic TB ( $p < 0.001$ ), indicating a lower bacterial burden in the subclinical group. Gunasekera *et al.* estimated the burden and risk factors for subclinical TB within the South African communities participating in the Zambia, South Africa Tuberculosis and AIDS Reduction trial [13]. They reported a crude prevalence of TB at 2222.1 cases per 100,000 population (95% CI 2053.4-2388.5), with 44.7% of these cases being subclinical. A significant association was found between current tobacco smoking (OR 2.37, 95% CI 1.41-3.99) and HIV-positive status (OR 3.26, 95% CI 2.31-4.61) with subclinical TB. The Indian TB prevalence survey identified several risk factors for TB, including low body mass index, alcohol use, smoking, older age groups, male gender, and diabetics [21]. Subclinical TB is a subset of active TB without symptoms and shares the same risk factors. Tang *et al.* conducted a retrospective study in China and found that out of 380 patients, 81.8% had active TB, and the remaining 18.2% had subclinical TB cases [23]. Younger individuals were shown to have a higher risk of having subclinical TB [23]. The sensitivity for detecting subclinical TB cases was 33.3% when combining culture and Xpert MTB/RIF assay. Additionally, a lower neutrophil-to-lymphocyte ratio and a significantly reduced prevalence of the Beijing genotype were observed in the subclinical TB group. However, the study was conducted in a low-prevalence setting. Bajema *et al.* reported that subclinical TB accounted for 23% of all TB cases among patients with untreated HIV in South Africa [24]. Patients with subclinical disease exhibited an intermediate degree of immunosuppression, with a median CD4 count of 136 (range: 72-312) cells/mm<sup>3</sup>. In a non-HIV population in South Korea, nearly 20% of TB patients were found to



**Figure 1.** The various stages of tuberculosis. TB, tuberculosis; TST, tuberculin test; IGRA, interferon  $\gamma$  release assay; PET, positron emission tomography.



have subclinical TB. Multivariable analysis indicated that being under 65 years of age was the only variable significantly associated with subclinical disease [25]. The authors noted a significantly lower proportion of smear positivity, culture positivity, and multiple lobe involvement in patients with subclinical disease compared to those with active TB. However, the treatment outcomes for subclinical TB were not significantly different from those for active disease. Carter *et al.* estimated the prevalence of subclinical pulmonary TB among household contacts (HHCs) of index TB patients in two South African provinces [26]. They reported a higher prevalence of subclinical pulmonary TB compared to clinical pulmonary TB, with rates of 2.3% (95% CI 1.7-3.1%) for subclinical TB and 1.0% (95% CI 0.6-1.5%) for symptomatic pulmonary TB. The prevalence of subclinical TB was notably higher in HIV-infected patients compared to HIV-uninfected patients (4.0 vs. 1.9;  $p=0.018$ ). Mtei *et al.* screened 498 HIV-1-infected individuals in Tanzania for active TB and reported the prevalence of active TB and subclinical TB as 71% and 29%, respectively [27]. The majority of patients with subclinical TB had initially received isoniazid preventive therapy. As a result, a high level of clinical suspicion for subclinical TB must be considered, especially in HIV-infected individuals and smokers, and appropriate investigations should be conducted before initiating TB preventive therapy. Rickman *et al.* [28], in the Tshepiso Study conducted in Soweto, South Africa, assessed the prevalence and impact of subclinical TB on maternal and pediatric outcomes in 235 HIV-infected pregnant women with TB, compared to matched HIV-positive, TB-negative pregnant women. They reported a 4.3% prevalence of subclinical TB among 162 women initially recruited as TB-negative controls. The risk of adverse effects was higher in infants born to HIV-infected mothers with subclinical TB compared to those born to TB-negative mothers. A TB prevalence survey from South Africa identified 234 patients as having bacteriologically confirmed pulmonary TB. Among these patients, approximately 57.7% exhibited no symptoms and were identified as positive solely through chest X-rays. Therefore, chest X-rays should be included as part of routine TB screening, alongside other diagnostic criteria [29]. A variety of factors contribute to the high prevalence of subclinical TB. These factors include individuals with a history of TB, smokers, HIV-positive people, especially those who are treatment-naïve, pregnant or postpartum period, and concomitant non-communicable diseases such as HHCs, prisoners, and miners [3]. The national prevalence-to-notification ratio for TB in India is 2.84:1 [19]. The prevalence surveys encompass both subclinical and clinical TB disease cases, while patients with symptomatic TB typically seek treatment at clinics and are subsequently notified. In 2021, an average of 1.9 million new TB patients (including both new and relapsed cases) were notified in India. This indicates a total prevalence of 5.3 million TB cases. If the global median prevalence is 50% [7], the median prevalence of subclinical TB in India is substantial, estimated at around 2.5 million cases. *Supplementary Table 1* shows the various studies on early-stage TB

mortality, although the window for intervention is limited. Other categories include slow progression with intermittent containment and spontaneous resolution. Individuals in these categories may remain infectious for a longer duration. Since they are generally recognized only after years of infection, those with slow progression have a higher chance of transmitting the infection. In a modeling study, Ryckman *et al.* examined the future trajectories of TB patients, including those who are smear-positive/negative and symptomatic/subclinical [30]. The anticipated duration of illness for patients with smear-negative subclinical TB at baseline was 4.8 (95% CI 3.3-8.4) months, and 86% to 89% of them had spontaneous resolution. Patients with smear-positive subclinical TB before diagnosis had an anticipated duration of illness of 15.9 (95% CI 11.1-23.5) months. Nearly all patients (96%) developed symptoms. Ultimately, 71% (range: 49-87%) received treatment, while 17% (range: 8-28%) succumbed to TB. Only 9% to 16% of future transmission events were caused by smear-negative subclinical TB, while 35% to 51% were caused by smear-positive subclinical TB. Ku *et al.* estimated the duration of asymptomatic, symptomatic, and care-seeking phases of TB disease based on data from 11 national datasets across Asia and Africa [31]. The duration of asymptomatic bacteriologically positive TB ranged from 4 to 8 months in African nations, while it exceeded 1 year in three Asian countries: Cambodia, Lao PDR, and the Philippines. People living with HIV have been observed to have a shorter duration. In Blantyre, Malawi, the duration of asymptomatic TB was 1.3 months (95% credible interval: 0.3-3.0) and 8.5 months (95% credible interval: 5.0-12.7) for HIV-positive and HIV-negative individuals, respectively. This finding is not surprising, as it is a well-known fact that TB disease progression is faster in cases of HIV-associated TB. In high-TB burden settings, where subclinical TB is common and there is a delay in health-care-seeking behavior, active approaches to TB screening and case-finding should be considered, as early detection could help avoid unfavorable consequences. In patients with subclinical TB, progression to active disease is not an inevitable or irreversible phenomenon. It can progress, regress, or even remain in a chronic disease state. Richards *et al.*, in a systematic review, assessed the outcome of untreated TB disease among the following three states [32]: minimal (non-infectious), subclinical (asymptomatic but infectious), and clinical (symptomatic and infectious). After 5 years, 40% [95% uncertainty intervals (UIs) 31.3-48.0] of those with subclinical disease at baseline had recovered, while 18% (95% UI 13.3-24) died from TB. About 14% (9.9-19.2) of individuals with subclinical disease at baseline still had infectious disease, and at 5 years, approximately 25% of patients with subclinical TB advanced to active disease. Moreover, among patients with subclinical disease at baseline, 50% (40.0-59.1) will never develop symptoms over 5 years. Spontaneous resolution is due to the self-clearance of *M. tuberculosis* bacilli. Lawn *et al.* identified 16 patients with subclinical TB who were culture-positive from Cape Town, South Africa [33]. They found that 75% of these patients developed TB symptoms between 5 days and 2 months of follow-up.

## Trajectory of subclinical tuberculosis

The natural history of subclinical TB is heterogeneous, with distinct trajectories noted in various groups. Kendall *et al.* identified three trajectories of TB in the absence of treatment [12]. Immunocompromised individuals and patients at the extremes of age typically exhibit rapid progression. Identifying these individuals during the subclinical stage may help prevent morbidity and

## Transmission dynamics of subclinical tuberculosis

Subclinical TB can be smear negative and culture positive, smear negative and molecular test positive, or smear positive. Subclinical TB can also be positive only on chest X-ray. Patients with chest X-ray suggestive of active TB with an initial microbiologically negative disease had approximately 10% annual risk



of progression to microbiologically positive disease [34]. Cough has long been associated with the production of infectious aerosols and the subsequent transmission of TB. Other aerosol-generating maneuvers, such as sneezing, singing, tidal breathing, and talking, may also contribute to aerosol generation [35,36]. Patients with active TB disease can produce bioaerosols during normal tidal breathing, with particle sizes ranging from 0.5 to 5  $\mu\text{m}$ , which facilitate transmission. Dinkele *et al.* assessed bioaerosols and viable *M. tuberculosis* from 38 people with treatment-naive, Xpert-positive pulmonary TB during three separate respiratory maneuvers: tidal breathing, forced vital capacity (FVC), and cough [37]. They reported 4.8-fold greater total particle counts in cough samples than either tidal breathing or FVC. However, all three maneuvers showed similar rates of positivity for viable *M. tuberculosis*. Further modeling revealed that tidal breathing produced more than 90% of the daily aerosolized *M. tuberculosis* among symptomatic TB patients, regardless of cough frequency. This is because an individual takes on average 22,000 breaths per day, compared to an upper quartile of 550 coughs in the same period. Furthermore, individual differences in bioaerosol generation outweigh the variability in bioaerosol production caused by respiratory maneuver types. Emery *et al.* estimated the contribution of subclinical TB to population-level TB transmission in a modeling study [38]. They collected data from 414 index cases and 789 HHCs from three prevalence surveys (Bangladesh, Philippines, and Vietnam) and one case-finding trial in Vietnam. About 68% (95% prediction interval, 27-92%) of global *M. tuberculosis* transmission was due to prevalent subclinical TB, although the CIs were wide. The transmission rate was 45% (95% prediction interval, 19-76%) in Nigeria and 84% (95% prediction interval, 60-95%) in Mongolia. The per-unit-time infectiousness of subclinical TB relative to clinical TB was 1.93 (95% prediction interval, 0.62-6.18). Therefore, subclinical TB contributes significantly to TB transmission and is similar in infectiousness to active clinical TB. Xu *et al.* measured TB transmission by using whole genome sequencing from TB clusters in the Valencia Region, Spain [39]. They found that 35.7% of TB transmission occurred well before symptom onset and when the patients were largely sputum negative. This clearly supports the concept of transmission in patients with subclinical disease. Naidoo *et al.* assessed the incidence, progression, and outcome of subclinical TB in 402 individuals living with HIV in South Africa [40]. Clinical-radiological-bacteriological screening for TB was done for 36 months. Forty-eight patients had bacteriologically confirmed recurrent TB, and out of these, 35.4% had subclinical TB. Furthermore, there was spontaneous resolution of subclinical TB in 35.3% of subjects who had bacteriologically confirmed TB. The majority of subclinical TB patients (82.3%) had positive cultures but negative smear results. While a low smear-positivity incidence suggests a lower bacillary burden, subclinical and clinical TB showed similar time to culture-positivity. This suggests a comparable bacterial burden and potential for transmission. Houben *et al.* described three stages of progression following TB infection [11]. In classical TB, both the incubation and pre-infectious period progress into clinical disease and infectiousness simultaneously. In the case of subclinical TB, the infectious period predates clinical TB. Subclinical TB may undergo self-cure or may enter a non-progressive stage. This will lead to a discrepancy between prevalence and estimated incidence. Based on multivariate analysis of data from Vietnam, Nguyen *et al.* estimated the adjusted risk ratio of TST positivity of 2.26 (95% CI 1.03-

4.96) in children living with patients of subclinical TB after adjusting for index smear status [41].

## Pathogenesis of early tuberculosis

The concept of early TB disease is not new. In a necropsy study involving 1225 patients with sudden and unexpected death due to non-TB causes, Medlar demonstrated active minimal TB in 96 lesions. The disease showed a predilection for the right apical posterior segment [42]. The pathogenesis of incipient and subclinical TB may be influenced by various factors, such as strain variation, different infection sites, diverse immunological milieu, and bacterial heterogeneity. A deeper understanding of the pathogenetic events in the early subclinical phase of TB will be facilitated by the development of novel diagnostics for subclinical TB. Esmail *et al.* conducted a whole genome transcriptomic analysis in 10 HIV-infected individuals with radiological evidence of subclinical TB and 15 active TB patients [43]. They found abundant expression of the classical complement pathway and Fc $\gamma$  receptors during the subclinical stage of the disease. They also noted increased levels of the circulating immune complex. The findings showed that antigen levels were found even in the early stages of paucibacillary disease. Moreover, transcripts associated with the Fc $\gamma$  receptors in the classical complement pathway increased in HIV-negative patients 12 months prior to the onset of illness. This insight has the potential to pave the way for developing newer therapies and diagnostics in the future. The *M. tuberculosis* lineages are also important since they typically exhibit distinct traits, including virulence, transmissibility, and disease severity [44].

## Radiological features of early-stage pulmonary tuberculosis

Among newly diagnosed HIV-negative patients with active subclinical TB, 68.2% showed typical adult-type pulmonary TB imaging abnormalities [45]. Other findings are intrathoracic lymph node enlargement (3.1%), bilateral disease (24.5%), cavitation (6.6%), and acinar shadows (7.1%), respectively. However, 17.5% of patients had a normal chest X-ray. Typically, cavities are small and often single. Compared to chest X-rays, computed tomography (CT) scans were 4.77 times (95% CI 1.95-11.66), 19.36 times (95% CI 8.05-46.52), and 3.23 times (95% CI 1.66-6.30) more likely to show lung cavitation, endobronchial spread, and moderate/far-advanced parenchymal disease. Thus, CT scans are more effective in identifying TB in its early stages. In a retrospective study, Lau *et al.* reported subclinical TB in approximately 20% of patients with culture-positive pulmonary TB [46]. In comparison to patients with clinical disease, subclinical pulmonary TB also has a higher prevalence among foreign-born individuals (90.2% vs. 79.6%), a higher likelihood of having smear-negative TB (88.2% vs. 43.5%), and a longer median time for culture positivity [18 days (IQR 14-25 days) vs. 12 days (IQR 7-17 days)]. In asymptomatic patients, chest X-ray is a crucial tool in active TB diagnosis as it guides subsequent microbiological testing. However, in this study, 86.4% of patients had either no or minimal parenchymal abnormalities. In comparison to the panel of expert radiologists, Long *et al.* found that field radiologists were less likely to report cavitation, a typical pattern, and parenchymal disease (74.9% vs. 81.3%, 62.4% vs. 70.0%, and 3.4% vs. 7.6%, respectively) in patients with subclinical pulmonary TB [47]. In Alberta,



Canada, Heffernan *et al.* evaluated the frequency of subclinical TB in patients with peripheral lymph node TB [48]. About 12.9% of patients with no symptoms and normal lung parenchyma, and 66.7% of individuals with both had positive sputum cultures. About 50% of individuals with a normal chest X-ray but a positive culture also had a normal CT thorax. As a result, pulmonary TB linked to peripheral lymph nodes may be subclinical. Since chest radiography is frequently recommended, widespread TB preventative therapy may also identify a significant proportion of people with subclinical TB. Ryckman *et al.* demonstrated that symptom-based active case finding (ACF) will only prevent less than 50% of future transmission [30]. However, 62 to 78% transmission may be avoided if patients with baseline bacterial burdens were identified. Therefore, even though they may burden healthcare in settings with limited resources, additional tests such as bacteriological investigations should be done. Han *et al.* evaluated the radiological features in 66 HIV-negative patients with bacteriologically proven early TB and reported well-defined solid nodules in the upper lobes and superior segments of the lower lobe as the most common imaging findings [49]. The adjusted OR for the progression to active TB in the presence of risk factors was 8.59. Positron emission tomography in conjunction with CT (PET-CT) is one option that can pick up early-stage TB. Increased 2-deoxy-2-[18F]fluorodeoxy-glucose (FDG) PET-CT scan in TB is caused by metabolically active cells such as macrophages and neutrophils [50]. Esmail *et al.* evaluated 35 asymptomatic, treatment-naïve, HIV-1-infected individuals with a PET-CT scan [51]. These individuals had latent TB based on a positive QuantiFERON-TB Gold in tube test. The patients had culture negativity, no abnormalities on chest X-rays, and CD4 T cell counts of  $\geq 350/\text{mm}^3$ . The patients with subclinical TB were significantly more likely to have abnormal FDG uptake within the mediastinal lymph nodes as compared to 25 participants without subclinical TB (80% vs. 32%;  $p=0.022$ ).

## Community-based screening

Community-based screening would be the most effective method to diagnose subclinical TB. According to the World Health Organization (WHO) consolidated guideline on systematic TB screening, in regions where the TB prevalence is  $\geq 0.5\%$ , the general population should be subjected to systematic screening. Symptom-based screening, chest X-rays, and rapid molecular diagnostic tests are the tools used in systematic screening. Computer-aided detection (CAD) can be applied to the interpretation of chest X-ray images [52]. In a systematic review of community-based ACF, Burke *et al.* found that ACF could be effective in modifying TB epidemiology if implemented with high coverage and intensity [53]. In the cluster-randomized trial conducted over 3 years in Vietnam, Marks *et al.* compared active community-based screening with passive case detection [54]. There were 42,150 participants in the intervention group and 41,680 participants in the control group. In the intervention arm, they screened the population with Xpert MTB/RIF and chest X-rays. They observed a reduction in the prevalence of Xpert test-positive, culture-confirmed pulmonary TB from the first year to the fourth year by 64%. In the DETEC TB trial, the mobile van approach was found to be more effective in detecting previously undiagnosed smear-positive TB than screening by door-to-door visits at 6-month intervals (adjusted risk ratio 1.48, 95% CI 1.11-1.96,  $p=0.0087$ ) [55]. In a modeling study, Dowdy *et al.* assessed the effects of various TB case-finding strategies on subclinical, pre-

diagnostic disease, and clinical phases at the population level [56]. In the pre-diagnostic phase, symptoms exist, but a diagnosis has not been established. By year 10, the passive strategy will reduce the incidence of TB by 18% if the subclinical phase is disregarded, compared to 23% for the enhanced strategy and 18% for the active strategy. However, after incorporating the subclinical phase, the corresponding figures for the passive, enhanced, and active strategies were 11%, 6%, and 16%, respectively. Subclinical TB has the potential to reduce the current TB detection strategies, and an active strategy is better for TB detection at the population level.

In a cluster-randomized trial, Martinson *et al.* showed that targeted universal testing for TB in high-risk groups diagnosed more patients with TB per month compared to the current standard of care, symptom-directed TB testing [57]. They provided sputum Xpert Ultra and culture to individuals who were HIV-positive, HHCs with TB, or prior TB. By direct comparison, there was no increase in the number of TB patients diagnosed. However, compared to the previous year, the same clinic showed a 17% increment in TB patients diagnosed per month (incidence rate ratio 1.17, 95% CI 1.14-1.19,  $p<0.001$ ). The tools available at present to detect subclinical TB are symptom screening, chest radiology, and molecular diagnostics. Houben *et al.* suggested additional sputum, induced sputum, bronchoalveolar lavage, and bioaerosol sampling to detect additional infectious cases, as they are also contributing to mycobacterial transmission [58]. TB transmission from millions of individuals with subclinical TB must be stopped. Without achieving this, the goal of ending TB strategy by 2035 might not be met. In the future, we definitely need newer diagnostics that will meet the WHO-recommended target product profile (TPP). Based on the presently available tools, a large fraction of infectious TB will be missed. A delay in the diagnosis of subclinical TB may increase the risk of potential transmission of TB. Many new diagnostics are in the pipeline, particularly non-sputum-based ones [59].

## Biomarker

In a systematic review and meta-analysis, the reported sensitivity of sputum culture, smear microscopy, TST/IGRA, and chest X-ray for diagnosing subclinical TB were 77% (95% CI 43-99%), 15% (95% CI 4-29%), 64% (95% CI 33-90%), and 53% (95% CI 3-81%), respectively [60]. Microbial tests are less sensitive as the bacterial burden is less in subclinical TB. As a result, there is enormous potential to develop diagnostic techniques that can identify TB in its early stages. Non-sputum-based assays, such as host biomarkers, have great potential. Currently, TST and IGRA tests are employed as host biomarkers in TB. The new biomarkers include the *M. tuberculosis*-specific T-helper cell activation assays, RNA signatures, proteins such as RISK 6, and the RISK 11 score. The potential of a biomarker-based diagnostic is enormous. However, the novel tests should meet the TPPs as recommended by the WHO [61]. The TPPs should have a sensitivity and specificity of at least 75% (minimum) to 90% (optimum) for predicting active disease progression over a period of 2 years. This would make the number needed to treat about 10 to 25. Newer tests should have the following characteristics: first, they should be instrument-free or feasible with limited instrumentation. Secondly, the samples should be easily accessible, such as blood, urine, or breath. Moreover, they should be able to discriminate between different states of TB [62-64]. The TPP should also be able to detect individuals with incipi-



ent TB who are likely to develop clinical disease within the next 2 years and who would benefit from TB preventive therapy. Transcriptomes help identify incipient TB. Sivakumaran *et al.* evaluated 35 incipient TB and 12 subclinical TB cases in Southern India, along with corresponding household active TB cases (n=11) and household controls (n=39), using transcriptional and protein profiling [64]. An 11-gene signature (*ABLM2*, *C20orf197*, *CTC-543D15.3*, *CTD-2503O16.3*, *HLADRB3*, *METRNL*, *RAB11B-AS1*, *RP4-614C10.2*, *RNA5SP345*, *RSUIP1*, and *UACA*) was found to have very good discriminatory power in differentiating between subclinical and incipient TB. They also identified eight protein signatures with good to moderate discriminatory power that might distinguish subclinical and incipient TB. In a systematic review and individual participant data meta-analysis, Gupta *et al.* evaluated 17 candidate messenger RNA (mRNA) signatures in a pooled dataset from four eligible studies comprising 1126 samples [65]. In this dataset, 183 samples from 127 incipient TB cases were included. They detected eight signatures comprising 1-25 transcripts that discriminated subjects with incipient TB from controls and predominantly expressed interferon and tumor necrosis factor-inducible gene expression. Within 2 years, the eight signatures had similar diagnostic accuracy for incipient TB patients. The area under the receiver operating characteristic curve (AUC) ranged from 0.70 (95% CI 0.64-0.76) to 0.77 (95% CI 0.71-0.82). Unfortunately, none of the 24 signatures met the minimum WHO TPP for incipient TB biomarkers over 2 years, except when applied to 3-6-month intervals. The CORTIS trial used an RNA transcriptomic signature of TB known as RISK11 in order to predict the risk of future TB. Additionally, they assessed the 3-month duration of weekly isoniazid and rifapentine (3HP) preventive treatment in South African volunteers who tested positive for RISK11 [66]. In individuals with a positive and negative RISK11 profile and without therapy, the prevalence of culture-positive illness was 4.1% and 0.78%, respectively. Over 15 months, the incidence of TB in patients with a positive RISK11 signature (3HP negative and without treatment) but no culture at baseline was 2.09/100 person-years. In those who tested negative for RISK11, the comparable value was 0.80/100 person-years. The trial has shown good discriminatory power in detecting prevalent or incident TB disease over 15 months. The optimal capacity to predict progression to active TB disease was limited to a 6-month timeframe. The test performed well in symptomatic prevalent TB, but its effect was less in asymptomatic prevalent TB (e.g., subclinical TB). Since asymptomatic prevalent TB has a limited specificity, people with a negative risk score may nonetheless be TB positive. However, the weekly 3HP regimen in RISK11-positive individuals did not reduce the progression to TB. Zak *et al.* have found that blood RNA signatures can predict the progression of TB [67]. In the 12 months preceding TB diagnosis, they identified 16 gene signatures that predicted the disease progression with a sensitivity of 66.1% (95% CI 63.2-68.9) and a specificity of 80.6% (79.2-82.0). The gene signature is known as *Zak16*. The Xpert MTB Host Response (MTB-HR) assay is a new point-of-care finger stick blood test that has been developed by Cepheid. The mRNA expression of three genes-guanylate binding protein 5 (*GBP5*), dual specificity phosphatase 3 (*DUSP3*), and Krüppel-like factor 2 (*KLF2*) was used to generate a "TB score". Both *GBP5* and *DUSP3* mediate pro-inflammatory responses and are upregulated in TB. Sutherland *et al.* compared the accuracy of the Cepheid GeneXpert MTB-HR prototype to the GeneXpert Ultra results and a composite microbiological score (GeneXpert Ultra and liquid culture) in adults with

clinical TB in three African countries as well as Vietnam [68]. Patients were classified as having TB or other respiratory diseases. When compared to GeneXpert Ultra, the Xpert-MTB-HR-Prototype TB score has an AUC of 0.94 (95% CI 0.91-0.97) to distinguish between active TB and other respiratory diseases. The sensitivity and specificity were 87% (95% CI 77-93%) and 94% (88-97%), respectively, independent of geographic area or HIV infection status. These assays met the WHO minimum TPP for a point-of-care triage test for TB. However, studies need to be done in subclinical TB when alterations in gene expression can be minimal. Wanchu *et al.* evaluated two biomarkers, Malate Synthase and MPT51, in both TB and HIV-TB coinfecting patients in India and reported high sensitivity and specificity for TB diagnosis [69]. The presence of concurrent HIV infection, the location of TB infection, or the lack of pulmonary symptoms in HIV/TB patients do not affect the performance of these biomarkers. Results also demonstrate the potential of these biomarkers for identifying early TB in HIV-infected but TB-negative subjects at high risk for TB. Penn-Nicholson identified a host-blood transcriptomic signature known as RISK6 and reported a receiver-operating characteristic curve value over 85% for the diagnosis of subclinical and clinical TB disease in HIV-uninfected and HIV-infected persons, respectively. When the test was run on finger-prick capillary blood samples, it revealed no difference in performance between venous and capillary blood. In addition, RISK6 scores showed a correlation with lung immunopathology activity, tracked response, and predicted treatment failure [70]. The use of blood RNA signatures as a diagnostic modality is very promising. Moreover, it also has the potential to be a point-of-care test with rapid turnaround times. However, blood biomarker-based diagnostics do have several limitations. Mulega *et al.* demonstrated that viral infections can result in transient false-positive results from the RISK11 whole-blood transcriptome signature, which may have impacted the clinical trial's outcome [71]. Both rhinovirus and coronavirus infections have been linked to this. Moreover, RISK11 signature scores are elevated in HIV infection [72]. A sizable fraction of patients with incipient disease may undergo self-regression. This will give rise to a false positive test [73]. In addition, the progression of early TB is quite variable. Some individuals might progress more slowly than others. Those who progress more quickly will test positive at the beginning of clinical illness. Lastly, gene expression will be variable in early childhood diseases and immunocompromised hosts. The best indication of a biomarker is the recent HHCs. Figure 2 shows the flow chart depicting the diagnostic approach to early-stage TB.

## Computer-aided diagnostic

The WHO has recommended that CAD software programs may be used for the interpretation of digital chest X-rays in individuals 15 years of age and older for the purpose of TB screening [52]. Qin *et al.* assessed the efficacy of five artificial intelligence (AI) algorithms for triaging TB patients in Dhaka, Bangladesh, and reported that all five AI-based algorithms performed better than the radiologists [74]. Therefore, AI-based X-ray reading is accurate and can be implemented in high-burden settings. Increasing use of AI-based tools will identify a large number of bacteriologically negative TB. Patients with radiologically positive TB can progress from 30% to 50% over a period of 4-6 years to culture-confirmed TB [75,76].




## *Mycobacterium tuberculosis* in aerosol

The detection of *M. tuberculosis* bacilli or DNA in aerosols belongs to the late prototype test category [57]. The bacilli or DNA are captured with capture filters, absorbent materials, or blow tubes with a capture filter. In a longitudinal study, Williams *et al.* detected *M. tuberculosis* DNA in 86% of facemasks and 21% of sputum samples [77]. They performed an XpertMTB/RIF Ultra assay on the sputum and facemask samples. Patients who tested positive for face masks but sputum negative were further assessed for 20 weeks using bronchoscopy, PET-CT, and sputum analysis. The exhaled DNA did not exhibit any diurnal pattern. Additionally, no association was observed between exhaled *M. tuberculosis* in face masks and cough frequency, sputum bacillary content, or chest radiographic disease severity. *M. tuberculosis* was found *via* facemask sampling four times more frequently than in sputum samples. Furthermore, it also aids in early diagnosis, up to 6 weeks before conventional sputum diagnosis. The mechanism of infected bioaerosol production can be cough-independent, which suggests the infectivity of subclinical TB [78]. Tidal breathing produces aerosols by the bronchiole fluid film burst mechanism [79]. Collecting samples from tongue swabs is a safe and easy-to-collect method for patients with pulmonary TB. The testing is done with the rapid molecular method. Using sputum Xpert Ultra as the reference standard, Andama *et al.* showed that tongue swabs Xpert Ultra had a sensitivity and specificity of 77.8% (95% CI 64.4-88.0) and 100.0% (95% CI 97.2-100.0), respectively [80]. Using sputum Xpert Ultra and sputum mycobacterial culture as microbiological reference standards, sensitivity was 72.4% (95% CI 59.1-83.3) and specificity was unchanged. Further optimization of tongue swab analysis is needed to achieve parity with sputum-based molecular testing for

TB. Sputum-free diagnostic methods look promising for future TB diagnostics. TB diagnostics can be useful for triaging or for confirmation of diagnosis. A triage test will guide us in determining who among the presumptive TB patients needs a confirmatory test [58].

## Compounds in breath

Variations in the signatures of volatile organic compounds in exhaled breath can be analyzed to facilitate the detection of pulmonary TB using electronic nose devices or gas chromatography [81]. Mougang *et al.* assessed the efficacy of an electronic nose for the diagnosis of TB in a Cameroon hospital [82]. They noted 88% accuracy, 90.8% sensitivity, 85.7% specificity, and 0.88 AUC compared to healthy controls. Similarly, Saktiawati *et al.* from Indonesia reported sensitivity and specificity of 85% (95% CI 75-92%) and 78% (95% CI 70-85%), 55% (95% CI 44-65%) and 42% (95% CI 34-50%), in the calibration and validation phases, respectively [83]. The negative predictive value in the blind prediction model was reported by Teixeira *et al.* as 100% [84]. Therefore, the electronic nose can be used as a rule-out test in the future. Another non-sputum-based test is the lipoarabinomannan (LAM) in urine. A recent development is the Fujifilm SILVAMP TB-LAM, which showed higher sensitivity irrespective of HIV status. In HIV-infected and HIV-uninfected patients, Comella-del-Barrio found a sensitivity of 70% (95% CI 35-92) and 65.7% (95% CI 48-80), respectively [85]. The tuberculin test and IGRA have a low positive predictive value (PPV) for progression to active TB. Diel *et al.*, in a meta-analysis of 28 studies including >30,000 individuals, found IGRAs to be more predictive than the TST for progression to active TB [86]. The pooled PPV for both IGRAs and TST is low; however, it is higher for



**Figure 2.** The flow chart depicting the diagnostic approach to early-stage tuberculosis. BALF, bronchoalveolar lavage fluid; PCR, polymerase chain reaction; CT, computed tomography.



IGRAs [2.7% (95% CI 2.3-3.2%)] than TST [1.5% (95% CI 1.2-1.7%)] ( $p < 0.0001$ ). The negative PPV for IGRAs and TST were 99.7% (95% CI 99.5-99.8%) and 99.4% (95% CI 99.2-99.5%), respectively ( $p < 0.01$ ). Moreover, in the high-risk group (recently infected or HIV-infected), the PPV for IGRAs rose to 6.8%, whereas it was only 2.4% for the TST. In children with subclinical TB, the best diagnostic outcome was noted when a combination of immunodiagnostic testing and imaging, followed by culture and molecular testing, was used (27.9%) [87].

## Treatment of incipient and subclinical tuberculosis

Given the potential for transmission, implementing a prevention and treatment strategy for subclinical TB disease is a crucial public health intervention. It has the potential to prevent negative health impacts and poor outcomes. However, there are few studies that have evaluated preventive therapy, treatment, and outcomes in early TB. The CORTIS trial evaluated the 3HP preventive therapy for 3 months in RISK11-positive participants in South Africa and reported negative results [66]. Patients with early-stage TB are not recruited in most clinical trials, making it difficult to study the effects of chemotherapy, vaccines, preventive therapy, and TB diagnostics on the subclinical and incipient stages of the disease. In order to fully understand and address subclinical and incipient TB, it is important to include both early-stage and clinical TB disease in research [11]. Currently, there is no specific guideline for managing subclinical TB. It may be challenging to offer the standard 6-month treatment to asymptomatic patients, leading to issues with adherence [88]. The traditional regimens for latent TB infection may be useful for incipient TB as well, but there is a lack of evidence. Therefore, further trials are needed to evaluate the use of newer drugs, shorter-duration regimens, host-directed therapy, and therapeutic vaccines in treating early-stage TB [89]. The WHO has advised TB preventive therapy with isoniazid for 36 months for TB infection in HIV-positive individuals in TB-endemic countries, as this may serve as the initial stage of incipient TB [3,90]. In a prospective study conducted in South Korea, Min *et al.* assessed the treatment outcomes of subclinical TB disease among HIV-uninfected patients [91]. Of the 420 individuals enrolled, 19.2% were found to have subclinical disease. In comparison to active disease, subclinical disease showed a significantly reduced proportion of acid-fast bacilli smear and culture positivity, as well as multiple lobe involvement. Although the proportion of favorable outcomes was higher in patients with subclinical disease, the OR was not statistically significant. Tan *et al.* evaluated the effectiveness of preventive therapy for subclinical TB among childhood HHCs in Lima, Peru [92]. They enrolled 793 TST-positive child HHCs (age  $\leq 15$ ) who underwent both symptom and chest X-ray screening and monitored them over the course of 1 year for the occurrence of TB disease. A normal chest X-ray was present in 784, and 451 received 6-month isoniazid preventive therapy. Preventive therapy was 72% effective in patients with normal chest X-rays, as incident TB occurred in 1.6% of those receiving preventive therapy vs. 4.6% of those not receiving it. In those with abnormal chest X-rays, preventive therapy efficacy was 65%, with TB occurring in 17% of those receiving it and 59% not receiving it. This suggests that preventive therapy is effective even in patients with subclinical TB. In a prospective study,

Ananda *et al.* assessed the course and outcomes of TB disease diagnosed by a community-based ACF program that was mobile and located in Yogyakarta, Indonesia [93]. They reported that 41.9% of patients with bacteriologically confirmed TB had subclinical TB. Multivariate analysis revealed weak evidence of reduced unsuccessful outcomes in cases of symptomatic vs. subclinical TB (adjusted OR 0.6, 95% CI 0.36-0.998). The American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines recommended a 4-month treatment regimen for HIV-uninfected adult patients with AFB smear- and culture-negative pulmonary TB [94]. Until we have specific studies involving early-stage TB for prevention and management, the treatment of subclinical TB should follow guidelines for conventional drug-susceptible TB disease. Before starting treatment, concurrent comorbidities, HIV infection, and potential drug-drug interactions should be assessed. Newer drug trials should include early TB cases to develop more effective treatment strategies. The SWIFT trial is a prospective, open-label, multicenter randomized controlled trial dedicated to subclinical TB only [95]. The result is pending. Prior to initiating TB preventive therapy, active TB disease must be ruled out, and chest radiology should be routinely performed. Dowdy *et al.* [96], in a modeling study, have proposed a comprehensive approach to reducing the incidence of TB. Interventions such as preventive therapy, case finding and diagnosis, and airborne infection control measures will be helpful in reducing transmission.

## Challenges and needs for the future

There are several flaws in the diagnostic tests that are currently in use. Furthermore, a lack of awareness about early-stage TB is common in resource-poor settings. A major knowledge gap exists regarding diagnostic strategies and treatment of early-stage TB. Because of its cross-reaction with non-tuberculous mycobacteria and the BCG vaccination, TST has a limited specificity. Availability and high cost are significant barriers to the IGRA's extensive application in resource-poor settings. Furthermore, there is no distinction made by these tests between TB infection and active TB disease. Chest X-rays have several limitations. Sputum culture can be positive in patients with normal chest X-rays. Therefore, relying on chest X-rays may underestimate subclinical TB by 10%. Chest X-rays have high sensitivity but poor specificity for pulmonary TB. In addition, there is significant intra- and inter-observer variability in the reading of chest X-rays [97]. Furthermore, screening for subclinical TB requires significant resources. There would be a US\$ 22,278 incremental cost-effectiveness ratio for each new TB case detected on chest X-ray screening as compared to only symptom-based screening [98]. Performing ACF regularly in a populous country is also a big challenge. Healthcare-seeking behavior is also poor in resource-poor settings. The sensitivity of microscopy is also low, particularly in immunocompromised patients. Laboratory infrastructures lack adequate infrastructure and manpower in resource-poor settings. Laboratories are often not adequate to manage a high volume of patients. Additionally, access to advanced diagnostic techniques is often limited in resource-poor settings, which poses a challenge in diagnosing early-stage TB. We need novel and accurate testing modalities to detect individuals who are diagnosed with incipient disease or subclinical TB. This area



needs funding and research at a level similar to the COVID-19 pandemic. An innovative test should ideally address the existing shortcomings and ideally be a point-of-care exam. The test must be available and cost-effective for middle- and low-income countries. Additionally, it should fulfill the WHO's recommended TPP. Adoption of TB preventive therapy on a large scale will lessen the incidence of active TB, including subclinical and incipient disease. Epidemiological data and genetic sequencing are required for the identification of transmission events. Diagnosis of early-stage TB requires cheaper and more sensitive detection methods. There is an urgent need to study treatment in various subsets of subclinical TB patients with a particular emphasis on shorter treatment duration. Additionally, we must ascertain how early identification affects post-TB sequelae.

## Conclusions

Subclinical and incipient TB may contribute a substantial proportion of the global TB burden. Patients with early-stage TB also have the potential to spread the disease. However, the current method of symptom-based screening may not detect cases of early TB. As a result, patients with early TB will continue to add to the overall global burden of TB. Furthermore, existing laboratory tests for TB are not able to confirm all cases of TB bacteriologically. Early identification of subclinical TB can significantly reduce the burden of TB and its long-term effects. If we proactively use active case-finding strategies to screen individuals who do not exhibit symptoms, we can achieve significant progress. Similarly, a validated biomarker-based approach may also be helpful in the diagnosis of various spectrums of TB diseases. Chest imaging-based community-based screening is crucial for the early detection of subclinical TB. This will help tremendously in achieving the target of the end-TB strategy. There are still many gaps that need to be addressed in the future. The best screening technique and treatment plan for subclinical TB need to be identified. The biomarker-based tests have great potential for TB diagnosis in the near future. The number of drugs and the duration of treatment are not clear and need future clinical trials. Further research and advancements in the future will provide us with the answers we need.

## References

- Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. *Nat Rev Microbiol* 2009;7:845-55.
- Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. *J Rheumatol Suppl* 2014;91:11-6.
- Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early-stages and progression of infection. *Clin Microbiol Rev* 2018;31:e00021-18.
- Migliori GB, Ong CWM, Petrone L, et al. The definition of tuberculosis infection based on the spectrum of tuberculosis disease. *Breathe* 2021;17:210079.
- Coussens AK, Zaidi SMA, Allwood BW, et al. Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise. *Lancet Respir Med* 2024;12:484-98.
- Kik SV, Schumacher S, Cirillo DM, et al. An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. *Eur Respir J* 2018;52:1800946.
- Frascella B, Richards AS, Sossen B, et al. Subclinical tuberculosis disease—a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology. *Clin Infect Dis* 2021;73:e830-41.
- Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. *Philos Trans R Soc Lond B Biol Sci* 2014;369:20130437.
- Allwood B, van der Zalm M, Makanda G, et al. The long shadow post-tuberculosis. *Lancet Infect Dis* 2019;19:1170-1.
- Stuck L, van Haaster AC, Kapata-Chanda P, et al. How “subclinical” is subclinical tuberculosis? an analysis of national prevalence survey data from Zambia. *Clin Infect Dis* 2022;75:842-8.
- Houben RMGJ, Esmail H, Emery JC, et al. Spotting the old foe—revisiting the case definition for TB. *Lancet Respir Med* 2019;7:199-201.
- Kendall EA, Shrestha S, Dowdy DW. The epidemiological importance of subclinical tuberculosis. A critical reappraisal. *Am J Respir Crit Care Med* 2021;203:168-74.
- Gunasekera K, Cohen T, Gao W, et al. Smoking and HIV associated with subclinical tuberculosis: analysis of a population-based prevalence survey. *Int J Tuberc Lung Dis* 2020;24:340-6.
- Esmail H, Dodd P J, Houben RMG J. Tuberculosis transmission during the subclinical period: could unrelated cough play a part? *Lancet Respir Med* 2018;6:244-6.
- Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. *Eur Respir J* 2015;45:1479-81.
- Lin L, Yang ZF, Zhan YQ, et al. The duration of cough in patients with H1N1 influenza. *Clin Respir J* 2017;11:733-8.
- Patterson B, Wood R. Is cough really necessary for TB transmission? *Tuberculosis* 2019;117:31-5.
- Stuck L, Klinkenberg E, Abdelgadir Ali N, et al. Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis. *Lancet Infect Dis* 2024;24:726-36.
- Hamada Y, Quartagno M, Law I, et al. Association of diabetes, smoking, and alcohol use with subclinical-to-symptomatic spectrum of tuberculosis in 16 countries: an individual participant data meta-analysis of national tuberculosis prevalence surveys. *EClinicalMedicine* 2023;63:102191.
- Onozaki I, Law I, Sismanidis C, et al. National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned. *Trop Med Int Health* 2015;20:1128-45.
- Government of India. National TB prevalence survey in India 2019-2021. Available from: <https://tbcindia.mohfw.gov.in/wp-content/uploads/2023/05/25032022161020NATBPSReport.pdf>. Accessed: 6/11/2023.
- Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. *Thorax* 2011;66:669-73.
- Tang P, Liang E, Zhang X, et al. Prevalence and risk factors of subclinical tuberculosis in a low-incidence setting in China. *Front Microbiol* 2022;12:731532.
- Bajema KL, Bassett IV, Coleman SM, et al. Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort. *BMC Infect Dis* 2019;19:14.
- Min J, Chung C, Jung SS, et al. Clinical profiles of subclinical



- cal disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea. *BMC Pulm Med* 2020;20:316.
26. Carter N, Webb EL, Lebina L, et al. Prevalence of subclinical pulmonary tuberculosis and its association with HIV in household contacts of index tuberculosis patients in two South African provinces: a secondary, cross-sectional analysis of a cluster-randomised trial. *BMC Glob Public Health* 2023;1:21.
  27. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. *Clin Infect Dis* 2005;40:1500-7.
  28. Rickman HM, Cohn S, Lala SG, et al. Subclinical tuberculosis and adverse infant outcomes in pregnant women with HIV. *Int J Tuberc Lung Dis* 2020;24:681-5.
  29. Moyo S, Ismail F, Van der Walt M, et al. Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey. *Lancet Infect Dis* 2022;22:1172-80.
  30. Ryckman TS, Dowdy DW, Kendall EA. Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications. *Proc Natl Acad Sci U S A* 2022;119:e2211045119.
  31. Ku CC, MacPherson P, Khundi M, et al. Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease with a Bayesian analysis of prevalence survey and notification data. *BMC Med* 2021;19:298.
  32. Richards AS, Sossen B, Emery JC, et al. Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study. *Lancet Glob Health* 2023;11:e684-92.
  33. Lawn SD, Kerkhoff AD, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. *AIDS* 2011;25:2190-1.
  34. Sossen B, Richards AS, Heinsohn T, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. *Lancet Respir Med* 2023;11:367-79.
  35. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. *Am Rev Respir Dis* 1967;95:435-42.
  36. Loudon RG, Roberts RM. Singing and the dissemination of tuberculosis. *Am Rev Respir Dis* 1968;98:297-300.
  37. Dinkele R, Gessner S, McKerry A, et al. Aerosolization of *Mycobacterium tuberculosis* by Tidal Breathing. *Am J Respir Crit Care Med* 2022;206:206-16.
  38. Emery JC, Dodd PJ, Banu S, et al. Estimating the contribution of subclinical tuberculosis disease to transmission – an individual patient data analysis from prevalence surveys. *Elife* 2023;12:e82469.
  39. Xu Y, Cancino-Muñoz I, Torres-Puente M, et al. High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. *PLoS Med* 2019;16:e1002961.
  40. Naidoo K, Moodley MC, Hassan-Moosa R, et al. Recurrent subclinical tuberculosis among antiretroviral therapy-accessing participants: incidence, clinical course, and outcomes. *Clin Infect Dis* 2022;75:1628-36.
  41. Nguyen HV, Tiemersma E, Nguyen NV, et al. Disease transmission by patients with subclinical tuberculosis. *Clin Infect Dis* 2023;76:2000-6.
  42. Medlar EM. Pathogenesis of minimal tuberculosis. *Am Rev Tuberc* 1948;58:583-611.
  43. Esmail H, Lai RP, Lesosky M, et al. Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. *Proc Natl Acad Sci U S A* 2018;115:E964-73.
  44. Coscolla M, Gagneux S. Consequences of genomic diversity in *Mycobacterium tuberculosis*. *Semin Immunol* 2014;26:431-44.
  45. Lau A, Lin C, Barrie J, et al. A comparison of the chest radiographic and computed tomographic features of subclinical pulmonary tuberculosis. *Sci Rep* 2022;12:16567.
  46. Lau A, Lin C, Barrie J, et al. The radiographic and mycobacteriologic correlates of subclinical pulmonary TB in Canada: a retrospective cohort study. *Chest* 2022;162:309-20.
  47. Long R, Lau A, Barrie J, et al. Limitations of chest radiography in diagnosing subclinical pulmonary tuberculosis in Canada. *Mayo Clin Proc Innov Qual Outcomes* 2023;7:165-70.
  48. Heffernan C, Egedahl ML, Barrie J, et al. The prevalence, risk factors, and public health consequences of peripheral lymph node-associated clinical and subclinical pulmonary tuberculosis. *Int J Infect Dis* 2023;129:165-74.
  49. Han S, Yoon SH, Goo JM, Yim JJ. Radiological features and progression of incipient active pulmonary tuberculosis according to risk factors. *Int J Tuberc Lung Dis* 2019;23:698-706.
  50. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. *Neoplasia* 2005;7:369-79.
  51. Esmail H, Lai RP, Lesosky M, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. *Nat Med* 2016;22:1090-3.
  52. WHO. WHO consolidated guidelines on tuberculosis. Module 2: screening. Systematic screening for tuberculosis disease. 2021. Available from: <https://www.who.int/publications-detail-redirect/9789240022676>.
  53. Burke RM, Nliwasa M, Feasey HRA, et al. Community-based active case-finding interventions for tuberculosis: a systematic review. *Lancet Public Health* 2021;6:e283-99.
  54. Marks GB, Ho J, Nguyen PTB, et al. A direct measure of tuberculosis incidence - effect of community screening. *N Engl J Med* 2022;386:1380-2.
  55. Corbett EL, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. *Lancet* 2010;376:1244-53.
  56. Dowdy DW, Basu S, Andrews JR. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. *Am J Respir Crit Care Med* 2013;187:543-51.
  57. Martinson NA, Nonyane BAS, Genade LP, et al. Evaluating systematic targeted universal testing for tuberculosis in primary care clinics of South Africa: a cluster-randomized trial (The TUTT Trial). *PLoS Med* 2023;20:e1004237.
  58. Houben RMGJ, Esmail H, Cobelens F, et al. Tuberculosis prevalence: beyond the tip of the iceberg. *Lancet Respir Med* 2022;10:537-9.
  59. Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M, et al. Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all? *EBioMedicine* 2022;78:103939.
  60. Mahmoudi S, Hamidi M, Drain PK. Present outlooks on the prevalence of minimal and subclinical tuberculosis and current diagnostic tests: a systematic review and meta-analysis. *J Infect Public Health* 2024;17:102517.
  61. WHO. Consensus meeting report. development of a target prod-



- uct profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Available from: <https://www.who.int/publications/i/item/WHO-HTM-TB-2017.18>.
62. MacLean E, Broger T, Yerlikaya S, et al. A systematic review of biomarkers to detect active tuberculosis. *Nat Microbiol* 2019;4:748-58.
  63. Sivakumaran D, Ritz C, Gjoen JE, et al. Host blood RNA transcript and protein signatures for sputum-independent diagnostics of tuberculosis in adults. *Front Immunol* 2020;11:626049.
  64. Sivakumaran D, Jenum S, Srivastava A, et al. Host blood-based biosignatures for subclinical TB and incipient TB: a prospective study of adult TB household contacts in Southern India. *Front Immunol* 2023;13:1051963.
  65. Gupta RK, Turner CT, Venturini C, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. *Lancet Respir Med* 2020;8:395-406.
  66. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. *Lancet Infect Dis* 2021;21:354-65.
  67. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *Lancet* 2016;387:2312-22.
  68. Sutherland JS, van der Spuy G, Gindeh A, et al. TrENDx-TB Consortium. Diagnostic accuracy of the cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results. *Clin Infect Dis* 2022;74:2136-41.
  69. Wanchu A, Dong Y, Sethi S, et al. Biomarkers for clinical and incipient tuberculosis: performance in a TB-endemic country. *PLoS One* 2008;3:e2071.
  70. Penn-Nicholson A, Mbandi SK, Thompson E, et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. *Sci Rep* 2020;10:8629.
  71. Mulenga H, Musvosvi M, Mendelsohn SC, et al. Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. *Am J Respir Crit Care Med* 2021;204:1463-72.
  72. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, et al. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. *Lancet Glob Health* 2021;9:e841-53.
  73. Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. *Eur Respir J* 2020;55:1901957.
  74. Qin ZZ, Ahmed S, Sarker MS, et al. Tuberculosis detection from chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial intelligence algorithms. *Lancet Digit Health* 2021;3:e543-54.
  75. Cowie RL, Langton ME, Escreet BC. Diagnosis of sputum smear and sputum culture-negative pulmonary tuberculosis. *S Afr Med J* 1985;68:878.
  76. Okada K, Onozaki I, Yamada N, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. *Int J Tuberc Lung Dis* 2012;16:1619-24.
  77. Williams CM, Abdulwhhab M, Birring SS, et al. Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies. *Lancet Infect Dis* 2020;20:607-17.
  78. Patterson B, Bryden W, Call C, et al. Cough-independent production of viable Mycobacterium tuberculosis in bioaerosol. *Tuberculosis* 2021;126:102038.
  79. Johnson GR, Morawska L. The mechanism of breath aerosol formation. *J Aerosol Med Pulm Drug Deliv* 2009;22:229-37.
  80. Andama A, Whitman GR, Crowder R, et al. Accuracy of Tongue swab testing using Xpert MTB-RIF ultra for tuberculosis diagnosis. *J Clin Microbiol* 2022;60:e0042122.
  81. Nakhleh MK, Jeries R, Gharra A, et al. Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. *Eur Respir J* 2014;43:1522-5.
  82. Ketchanji Mougang YC, Endale Mangamba LM, Capuano R, et al. On-field test of tuberculosis diagnosis through exhaled breath analysis with a gas sensor array. *Biosensors* 2023;13:570.
  83. Saktiawati AMI, Stienstra Y, Subronto YW, et al. Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. *PLoS One* 2019;14:e0217963.
  84. Coronel Teixeira R, Ijdema D, et al. The electronic nose as a rule-out test for tuberculosis in an indigenous population. *J Intern Med* 2021;290:386-91.
  85. Comella-Del-Barrio P, Bimba JS, Adelakun R, et al. Fujifilm SILVAMP TB-LAM for the diagnosis of tuberculosis in Nigerian adults. *J Clin Med* 2021;10:2514.
  86. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. *Chest* 2012;142:63-75.
  87. Fritschi N, Wind A, Hammer J, Ritz N. Subclinical tuberculosis in children: diagnostic strategies for identification reported in a 6-year national prospective surveillance study. *Clin Infect Dis* 2022;74:678-84.
  88. Esmail H, Macpherson L, Coussens AK, Houben RMGJ. Mind the gap - managing tuberculosis across the disease spectrum. *EBioMedicine* 2022;78:103928.
  89. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Hostdirected therapies for bacterial and viral infections. *Nat Rev Drug Discov* 2018;17:35-56.
  90. WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. 2011. Available from: <https://www.who.int/publications/i/item/9789241500708>.
  91. Min Z, Chung C, Jung SS, et al. Subclinical tuberculosis disease and its treatment outcomes: a prospective cohort study in South Korea. *Eur Respir J* 2020;56:516.
  92. Tan Q, Huang C, Becerra M, et al. Effect of prevention therapy for subclinical tuberculosis in child household contacts. *Eur Respir J* 2022;60:565.
  93. Ananda NR, Triasih R, Dwihardiani B, et al. Spectrum of TB disease and treatment outcomes in a mobile community based active case finding program in Yogyakarta province, Indonesia. *Trop Med Infect Dis* 2023;8:447.
  94. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis* 2016;63:e147-95.
  95. Zhang W. Subclinical TB with innovative modified short-course regimens (SWIFT). 2023. Available from: <https://clinicaltrials.gov/study/NCT06153069>.



## Review

---

96. Dowdy DW, Grant AD, Dheda K, et al. Designing and evaluating interventions to halt the transmission of tuberculosis. *J Infect Dis* 2017;216:S654-61.
97. WHO. Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. Available from: <https://www.who.int/publications/item/9789241511506>.
98. Kim HY, Zishiri V, Page-Shipp L, et al. Symptom and digital chest X-ray TB screening in South African prisons: yield and cost-effectiveness. *Int J Tuberc Lung Dis* 2020;24:295-302.

---

*Online supplementary material:*

*Supplementary Table 1. The various studies on early-stage tuberculosis.*

---

Received: 8 March 2024.; Accepted: 21 October 2024; Early view: 8 January 2025.

Ethics approval and consent to participate: not applicable.

Patient consent for publication: not applicable.

Availability of data and materials: data available from the corresponding author upon request.

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

*This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).*

